Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1985 1
1989 2
1995 1
1996 2
1997 1
2001 4
2002 1
2003 1
2004 3
2005 4
2006 4
2007 2
2008 2
2009 6
2010 11
2011 7
2012 12
2013 9
2014 8
2015 16
2016 8
2017 17
2018 2
2019 6
2020 3
Text availability
Article attribute
Article type
Publication date

Search Results

125 results
Results by year
Filters applied: . Clear all
Page 1
Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial.
Geletneky K, Hajda J, Angelova AL, Leuchs B, Capper D, Bartsch AJ, Neumann JO, Schöning T, Hüsing J, Beelte B, Kiprianova I, Roscher M, Bhat R, von Deimling A, Brück W, Just A, Frehtman V, Löbhard S, Terletskaia-Ladwig E, Fry J, Jochims K, Daniel V, Krebs O, Dahm M, Huber B, Unterberg A, Rommelaere J. Geletneky K, et al. Mol Ther. 2017 Dec 6;25(12):2620-2634. doi: 10.1016/j.ymthe.2017.08.016. Epub 2017 Aug 24. Mol Ther. 2017. PMID: 28967558 Free PMC article. Clinical Trial.
Oncolytic virotherapy may be a means of improving the dismal prognosis of malignant brain tumors. The rat H-1 parvovirus (H-1PV) suppresses tumors in preclinical glioma models, through both direct oncolysis and stimulation of anticancer immune responses. This was th
Oncolytic virotherapy may be a means of improving the dismal prognosis of malignant brain tumors. The rat H-1 parvovirus (H-1P
Oncolytic Virotherapy for the Treatment of Malignant Glioma.
Foreman PM, Friedman GK, Cassady KA, Markert JM. Foreman PM, et al. Neurotherapeutics. 2017 Apr;14(2):333-344. doi: 10.1007/s13311-017-0516-0. Neurotherapeutics. 2017. PMID: 28265902 Free PMC article. Review.
Oncolytic viruses are designed to selectively target, infect, and replicate in tumor cells, while sparing surrounding normal brain. ...Oncolytic viral therapy for glioma remains promising and will undoubtedly impact the future of patient care....
Oncolytic viruses are designed to selectively target, infect, and replicate in tumor cells, while sparing surrounding normal brain. .
Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy?
Stepanenko AA, Chekhonin VP. Stepanenko AA, et al. Cancers (Basel). 2018 Dec 5;10(12):492. doi: 10.3390/cancers10120492. Cancers (Basel). 2018. PMID: 30563098 Free PMC article. Review.
Recent early phase trials with the recombinant adenovirus DNX-2401 (Ad5-delta24-RGD), polio-rhinovirus chimera (PVSRIPO), parvovirus H-1 (ParvOryx), Toca 511 retroviral vector with 5-fluorocytosine, heat shock protein-peptide complex-96 (HSPPC-96) and dendritic cell vaccin …
Recent early phase trials with the recombinant adenovirus DNX-2401 (Ad5-delta24-RGD), polio-rhinovirus chimera (PVSRIPO), parvovirus
Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1.
Moehler M, Goepfert K, Heinrich B, Breitbach CJ, Delic M, Galle PR, Rommelaere J. Moehler M, et al. Front Oncol. 2014 May 1;4:92. doi: 10.3389/fonc.2014.00092. eCollection 2014. Front Oncol. 2014. PMID: 24822170 Free PMC article. Review.
By generating tumor cell lysates in situ, oncolytic viruses overcome cellular tumor resistance mechanisms and induce immunogenic tumor cell death resulting in the recognition of newly released tumor antigens. This is in particular the case of the oncolytic parvov
By generating tumor cell lysates in situ, oncolytic viruses overcome cellular tumor resistance mechanisms and induce immunogenic tumo …
New Insights into Parvovirus Research.
Gallinella G. Gallinella G. Viruses. 2019 Nov 13;11(11):1053. doi: 10.3390/v11111053. Viruses. 2019. PMID: 31766142 Free PMC article.
The Special Issue of 'Viruses' dedicated to the 'New Insights into Parvovirus Research' aimed at presenting a 'state of the art' in many aspects of research in the field, at collecting the newest contributions on unresolved issues, and at presenting new approaches exploiti …
The Special Issue of 'Viruses' dedicated to the 'New Insights into Parvovirus Research' aimed at presenting a 'state of the art' in m …
Antiangiogenic Vascular Endothelial Growth Factor-Blocking Peptides Displayed on the Capsid of an Infectious Oncolytic Parvovirus: Assembly and Immune Interactions.
Grueso E, Sánchez-Martínez C, Calvo-López T, de Miguel FJ, Blanco-Menéndez N, Fernandez-Estevez M, Elizalde M, Sanchez J, Kourani O, Martin D, Tato A, Guerra M, Andrés G, Almendral JM. Grueso E, et al. J Virol. 2019 Sep 12;93(19):e00798-19. doi: 10.1128/JVI.00798-19. Print 2019 Oct 1. J Virol. 2019. PMID: 31315994 Free PMC article.
To target the oncolytic parvovirus minute virus of mice (MVM) to the tumor vasculature, we studied the functional tolerance, evasion of neutralization, and induction of α-VEGF antibodies of chimeric viruses in which the footprint of a neutralizing monoclonal antibod …
To target the oncolytic parvovirus minute virus of mice (MVM) to the tumor vasculature, we studied the functional tolerance, e …
H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future.
Bretscher C, Marchini A. Bretscher C, et al. Viruses. 2019 Jun 18;11(6):562. doi: 10.3390/v11060562. Viruses. 2019. PMID: 31216641 Free PMC article. Review.
The rat protoparvovirus H-1PV is nonpathogenic in humans, replicates preferentially in cancer cells, and has natural oncolytic and oncosuppressive activities. ...
The rat protoparvovirus H-1PV is nonpathogenic in humans, replicates preferentially in cancer cells, and has natural oncolytic and on …
Preclinical Testing of an Oncolytic Parvovirus in Ewing Sarcoma: Protoparvovirus H-1 Induces Apoptosis and Lytic Infection In Vitro but Fails to Improve Survival In Vivo.
Lacroix J, Kis Z, Josupeit R, Schlund F, Stroh-Dege A, Frank-Stöhr M, Leuchs B, Schlehofer JR, Rommelaere J, Dinsart C. Lacroix J, et al. Viruses. 2018 Jun 3;10(6):302. doi: 10.3390/v10060302. Viruses. 2018. PMID: 29865280 Free PMC article.
Here, in the context of the search for novel therapeutic options, the potential of oncolytic protoparvovirus H-1 (H-1PV) to treat Ewing sarcoma was evaluated, its safety having been proven previously tested in adult cancer patients and its oncolytic efficacy demonst …
Here, in the context of the search for novel therapeutic options, the potential of oncolytic protoparvovirus H-1 (H-1PV) to treat Ewi …
Oncolytic parvoviruses: from basic virology to clinical applications.
Marchini A, Bonifati S, Scott EM, Angelova AL, Rommelaere J. Marchini A, et al. Virol J. 2015 Jan 29;12:6. doi: 10.1186/s12985-014-0223-y. Virol J. 2015. PMID: 25630937 Free PMC article. Review.
Furthermore, the development of novel parvovirus-based anticancer strategies with enhanced specificity and efficacy is discussed, in particular the development of second and third generation vectors and the combination of parvoviruses with other anticancer agents. L …
Furthermore, the development of novel parvovirus-based anticancer strategies with enhanced specificity and efficacy is discussed, in …
Atomic Resolution Structure of the Oncolytic Parvovirus LuIII by Electron Microscopy and 3D Image Reconstruction.
Pittman N, Misseldine A, Geilen L, Halder S, Smith JK, Kurian J, Chipman P, Janssen M, Mckenna R, Baker TS, D'Abramo A Jr, Cotmore S, Tattersall P, Agbandje-McKenna M. Pittman N, et al. Viruses. 2017 Oct 30;9(11):321. doi: 10.3390/v9110321. Viruses. 2017. PMID: 29084163 Free PMC article.
This virus group includes H-1 parvovirus (H-1PV) and minute virus of mice (MVM). However, LuIII displays enhanced oncolysis compared to H-1PV and MVM, a phenotype mapped to the major capsid viral protein 2 (VP2). ...
This virus group includes H-1 parvovirus (H-1PV) and minute virus of mice (MVM). However, LuIII displays enhanced oncolysis compared …
125 results
Jump to page
Feedback